Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study

Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.4 mg compared with Eli Lilly and Co.’s LLY tirzepatide treatment in people with overweight or obesity and established CVD without diabetes.DataCompared with tirzepatide, Wegovy showed a significant 57% greater risk reduct ...